Market Currents
Results from a Phase II trial of a cholestoral drug from Regeneron (REGN +0.7%) were good but...
-
Monday, March 26, 2012, 12:14 PM ETResults from a Phase II trial of a cholestoral drug from Regeneron (REGN +0.7%) were good but were upstaged at a heart conference by the outcome of a Phase I trial of a rival treatment from Amgen (AMGN +1.5%), which was better. Still, both drugs have a long way to go before they'll be able to enter a market that could be worth $20B/year.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
